Infectious agent | Antibiotic regimen¶ | Dosing |
Staphylococci, methicillin susceptible | One of the following: | |
Cefadroxil | 500 to 1000 mg twice daily | |
Cephalexin | 500 mg 3 or 4 times daily, or 1000 mg 2 or 3 times daily | |
Dicloxacillin | 500 mg 3 or 4 times daily | |
Flucloxacillin | 500 mg 3 or 4 times daily | |
Staphylococci, methicillin resistantΔ | One of the following: | |
Trimethoprim-sulfamethoxazole | 1 double-strength tablet twice daily | |
Doxycycline | 100 mg twice daily | |
Minocycline | 100 mg twice daily | |
Clindamycin | 600 mg 3 times daily | |
Gram-negative organisms | One of the following: | |
Trimethoprim-sulfamethoxazole | 1 double-strength tablet twice daily | |
Ciprofloxacin◊ | 500 mg twice daily | |
Levofloxacin◊ | 500 mg once daily | |
Penicillin-sensitive streptococci and enterococci | One of the following: | |
Amoxicillin | 500 mg 2 to 3 times daily | |
Penicillin V K | 500 mg 2 to 4 times daily | |
Cutibacterium (formerly Propionibacterium) acnes | One of the following: | |
Amoxicillin | 500 mg 2 to 3 times daily | |
Penicillin V K | 500 mg 2 to 3 times daily |
PJI: prosthetic joint infection.
* Initial treatment of PJI consists of definitive antibiotic therapy (refer to the separate UpToDate table); suppressive therapy is warranted only for individuals with retained hardware and/or necrotic bone not amenable to complete debridement. The optimal duration of oral suppressive antibiotic therapy is uncertain. Refer to the UpToDate topic on the treatment of PJI for further discussion.
¶ The choice of antibiotic regimen should be based on susceptibility, as well as patient drug allergies, intolerances, and potential drug-drug interactions or contraindications to a specific agent.
Δ The agents listed for methicillin-resistant staphylococci may be used for suppression of methicillin-susceptible staphylococci in patients with beta-lactam allergy or intolerance, provided the organism is susceptible.
◊ Ciprofloxacin and levofloxacin have activity against Pseudomonas aeruginosa.